PPWR Compliance for Pharma Importers France: The Readiness Guide

PPWR Compliance for Pharma Importers France is the set of packaging obligations a company must meet when it brings pharmaceutical products packaged abroad onto the French market under Regulation (EU) 2025/40. From 12 August 2026, every packaging type needs a Declaration of Conformity backed by technical documentation, and each importer must decide whether it is acting as a packaging “manufacturer”, an EPR “producer”, or both because in France, it is almost always both.

Key takeaways

• PPWR applies from 12 August 2026 there is no grace period for packaging placed on the market on or after that date.
• Two roles, two obligations. The “manufacturer” owns the Declaration of Conformity (Annex VIII) and technical file (Annex VII); the “producer” owns French EPR registration, IDU, Triman/Info-Tri, eco-fees.
• Importers usually are not the manufacturer unless they rebrand or modify packaging, which reclassifies them as a “deemed manufacturer”.
• Medicine packaging is in scope even when it cannot be freely redesigned; PFAS limits, minimisation and recyclability rules still apply.
• It is a documentation problem at scale the right DoC for the right SKU, retrievable within 10 days of an authority request.

What does PPWR compliance for pharma importers France actually require?

PPWR compliance for pharma importers France requires two parallel workstreams: a Declaration of Conformity (Annex VIII) with supporting technical documentation (Annex VII) for every packaging type, and full French Extended Producer Responsibility registration an IDU from ADEME via a producer responsibility organisation, plus Triman and Info-Tri labelling on household packaging.

The Packaging and Packaging Waste Regulation replaces a 30-year-old directive with a single, directly applicable rulebook across all 27 Member States. For a pharma importer, that means the packaging around your medicines cartons, leaflets, blister foils, cold-chain shippers is now governed by the same conformity logic as the medicine itself is governed by pharmaceutical law. PPWR compliance for pharma importers France therefore lands in two places at once: the EU-level conformity file that proves the packaging is legal, and the French EPR system that funds and labels its end-of-life collection.

For PPWR compliance for pharma importers France, most of the work due in August 2026 is documentary rather than a packaging redesign. But documentary work at pharma scale hundreds of SKUs, multiple suppliers, cold-chain variants is exactly where importers get caught short.

Understand PPWR Compliance RequirementsDiscover the key requirements, documentation and data you need to prepare for PPWR compliance.→ Read the Blog

Are you a manufacturer or a producer? The distinction that decides everything

Under PPWR, a “manufacturer” is whoever designs or makes packaging (or has it made) and markets it under their own name or trademark, and owns the Declaration of Conformity. A “producer” is whoever first makes the packaged product available in a Member State and owns Extended Producer Responsibility. A French pharma importer is usually the producer, and only becomes the manufacturer if it rebrands or modifies the packaging.

This is the single most expensive misunderstanding in PPWR compliance for pharma importers France. Being registered with Citeo does not give you a Declaration of Conformity. Holding a Declaration of Conformity does not satisfy French EPR. They are different roles, anchored in different articles, with different evidence.

As a producer (the usual case)

You are almost always the EPR producer because you are first to place the packaged medicine on the French market.

You register with a producer responsibility organisation (Citeo, Adelphe or Léko), obtain your unique identifier (IDU) via ADEME, report volumes by material, and pay eco-contributions.

From 12 August 2026, if you are not established in France you must appoint an EPR authorised representative in France one per country, with no size exemption.

As an importer verifying the manufacturer

You do not draw up the Declaration of Conformity yourself you request it from the packaging manufacturer and retain a copy.

You must verify the manufacturer carried out the conformity assessment and holds the technical documentation before the packaging is placed on the EU market.

You must be able to present the correct Declaration of Conformity to French market surveillance within 10 days of a request.

Getting this split right is the foundation of PPWR compliance for pharma importers France; everything downstream is simply the evidence that proves each role.

If you repackage, co-brand, or alter medicine packaging in ways that affect conformity, PPWR reclassifies you as the manufacturer and the full Declaration of Conformity and Annex VII technical-file burden becomes yours.

Know Your Role Under PPWRUnderstand who is responsible for what and what your business needs to do.→ Read the Blog

Which PPWR obligations hit pharma packaging in France first?

From 12 August 2026, pharma importers must have a signed Declaration of Conformity per packaging type, comply with the PFAS food-contact restriction and heavy-metal limits, and meet packaging-minimisation and recyclability rules. Design-for-recycling grades, recycled-content minimums and the empty-space cap phase in later, toward 2030.

Pharmaceutical packaging carries constraints that FMCG packaging does not: child-resistant closures, tamper evidence, mandatory patient leaflets, serialisation, and cold-chain integrity. PPWR does not waive these but it does not exempt the packaging either. The practical reading for PPWR compliance for pharma importers France is that you satisfy the sustainability requirements within the envelope your pharmaceutical obligations allow, and you document why any constraint is technically unavoidable.

• Due now (Aug 2026): Declaration of Conformity per packaging type, PFAS food-contact ban, heavy-metal limits, minimisation and recyclability evidence in the Annex VII file.
• Retention: keep the DoC and technical file 5 years for single-use packaging, 10 years for reusable measured from the last unit placed on the market.
• Phasing to 2030: design-for-recycling performance grades, recycled-content minimums and the empty-space limit for grouped and transport packaging.

PPWR Is Now in Effect. What Changes for Your Business?Understand the key requirements, responsibilities and next steps after August 2026.→ Read the Blog

How France’s EPR layer stacks on top: Triman, Info-Tri and the IDU

France runs the EU’s most demanding packaging EPR regime. On top of PPWR, pharma importers must display the Triman logo and Info-Tri sorting instructions on household packaging, register with a PRO, and carry an ADEME-issued IDU obligations rooted in France’s AGEC anti-waste law, not in PPWR itself.

Treating conformity and EPR as one workstream is the classic failure mode, because French enforcement tends to surface all of it at once during a market-readiness review: a missing Declaration of Conformity, an unposted IDU, and non-compliant on-pack labelling. For PPWR compliance for pharma importers France to hold up, the Triman logo, the Info-Tri instructions, the IDU on your commercial documentation, and the packaging DoC all have to be consistent with the materials you actually declare. Done properly, PPWR compliance for pharma importers France is one connected record rather than three disconnected ones.

PPWR compliance for pharma importers France is, underneath the legal language, a data problem: the right evidence, attached to the right packaging type, retrievable on demand. The TraceX PPWR platform is built to hold packaging-level records Declarations of Conformity, Annex VII technical files, supplier attestations, and EPR data points against each SKU in one data layer, so an importer can answer a market-surveillance request in days rather than scrambling across inboxes and supplier portals . The regulation rewards importers who treat documentation as a living system, not a one-off file.

Manual approach vs. the TraceX platform

A practical checklist for PPWR compliance for pharma importers France

Use the evaluation checklist below to pressure-test your PPWR compliance for pharma importers France before 12 August 2026. If you cannot produce the correct document for a given SKU inside ten days, treat that as a red flag, not a paperwork detail.

Buyer evaluation checklist

• Have you confirmed, per SKU, whether you are the producer, the manufacturer, or both?
• Do you hold a signed Declaration of Conformity (Annex VIII) for every packaging type placed on the French market?
• Is the supporting Annex VII technical documentation complete and current for each declaration?
• Are you registered with a French PRO (Citeo, Adelphe or Léko) with an ADEME-issued IDU?
• If not established in France, have you appointed an EPR authorised representative?
• Do Triman and Info-Tri labels match the materials you actually declare?
• Can you retrieve the correct file for any SKU within 10 days of a market-surveillance request?
• Do you have a retention plan (5 years single-use / 10 years reusable) with a clear owner?

Frequently Asked Questions